Trifluridine + Tipiracil
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TRIFLURIDINE-TIPIRACIL |
|---|---|
| Type | Drug |
| Aliases | LonsurfTAS-102Трифлуридин + Типірацил |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CRC DIS-GASTRIC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Drug Facts
| Class | Oral fluoropyrimidine prodrug + thymidine phosphorylase inhibitor (combination tablet) |
|---|---|
| Mechanism | Trifluridine (FTD) is a thymidine analog incorporated into DNA causing DNA dysfunction; rapidly degraded by thymidine phosphorylase (TP) in vivo, limiting bioavailability. Tipiracil hydrochloride (TPI) is a potent TP inhibitor that protects FTD from catabolism, enabling oral bioavailability + sustained tissue exposure. Active in fluoropyrimidine- refractory disease (distinct mechanism from 5-FU TS inhibition). |
| Typical dosing | 35 mg/m² (based on FTD component) PO BID days 1-5 + 8-12 of 28-day cycle (4 doses/week × 2 weeks, then 14-day rest). Take within 1 hour after meals (morning + evening). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
RECOURSE trial (Mayer 2015): 3L+ mCRC after standard chemo (FOLFOX, FOLFIRI, anti-EGFR/anti-VEGF) — TAS-102 vs placebo improved mOS 7.1 vs 5.3 mo (HR 0.68). SUNLIGHT trial (2023): TAS-102 + bevacizumab vs TAS-102 alone improved mOS 10.8 vs 7.5 mo (HR 0.61) — establishing combination as preferred over monotherapy in 3L+. Stop if ANC <500 prior to dose; allow ≥3 days recovery between cycles.
Used By
Regimens
REG-TRIFLURIDINE-TIPIRACIL-BEV- Trifluridine-Tipiracil + Bevacizumab (SUNLIGHT) — 3L+ mCRCREG-TRIFLURIDINE-TIPIRACIL-GASTRIC- Trifluridine-Tipiracil (TAGS) — 3L+ gastric/GEJREG-TRIFLURIDINE-TIPIRACIL-MONO- Trifluridine-tipiracil monotherapy (RECOURSE, 3L+ mCRC)